Background: Health research in Canada is funded by government, health charities, foundations and industry. We investigated levels of IBD research funding and the scientific impact of this research in Canada between 2013 and 2017.
Health research in Canada is funded by various levels of government, health charities, foundations and industry. Crohn's and Colitis Canada and the Canadian Institutes of Health Research (CIHR), in concert with valued partners, fund the majority of health research in inflammatory bowel diseases (IBD) in Canada. The intent of this section is to provide a historical view of IBD research funding and scientist ratings in Canada between 2013 and 2017, providing international comparisons where possible.
Two perspectives are provided: a look at the amount of funding of IBD research globally over the past five years and then a look at the same time period for Canada.
GLOBAL FUNDING
A global funding analysis was conducted using 'UberResearch's Dimensions' platform (www.uberresearch.com/dimensionsfor-funders/). Dimensions is a database developed by mining primarily publicly available research funding databases found on the internet. The developers of Dimensions obtain formal permission from all funding bodies included in the platform. A comprehensive list of funders of IBD research for the period 2013 to 2017 included in Dimensions is provided in Appendix A. Table 1 depicts total global funding for IBD research between 2013 and 2017. During this period, the United States invested the greatest amount: over 75% ($2.227 billion CAD) of the world's contribution. Canada ranked fourth after Belgium and the United Kingdom, investing 4% (over $119 million Canadian dollars [CAD] ) of the total IBD funding in the world.
FUNDING IN CANADA
Within this overview of Canada, the activities of the top two funders, CIHR and Crohn's and Colitis Canada, are presented in more detail, together with an overview of the types of funding mechanisms most frequently used during this period.
Quantifying Research Funding in Canada
To determine the extent of IBD funding in Canada, the Dimensions platform was used to identify the major funders (for methodology, see Appendix A). Once major funders were identified, total funding for the period 2013 to 2017 was confirmed by contacting the funders individually or retrieving data from their websites and manually confirming the information. Table 2 depicts total funding in Canada between 2013 to 2017 for IBD research by federal and provincial funding agencies and by Crohn's and Colitis Canada. Total funding during this five-year period was over $119 million, with $21.4 million to $27.8 million in annual investments. Funding data for other diseases with similar incidence and prevalence in Canada were obtained from the National Alliance of Provincial Health 
Funding by Crohn's and Colitis Canada
Crohn's and Colitis Canada is one of the largest nongovernment funders of Crohn's disease and ulcerative colitis in the world. Founded in 1974, the promise of Crohn's and Colitis Canada is to cure Crohn's disease and ulcerative colitis and to improve the lives of children and adults affected by these chronic diseases. In fulfilling this promise, Crohn's and Colitis Canada invests in research to increase understanding of, improve and expand treatment options for, and ultimately find the cure(s) for these life-long diseases. During the past five years (2013 to 2017), Crohn's and Colitis Canada invested an average of $6.4 million per year to support investigator-led research projects, targeted research initiatives, and fellowships and studentships to train the next generation of IBD researchers in Canada. In addition, Crohn's and Colitis Canada has held annual research conferences as part of the Meeting of the Minds education event to bring together scientists and health care providers to discuss the latest topics in research and IBD care.
FUNDING MECHANISMS

Priority-Driven IBD Research Funding in Canada
Priority-driven funding opportunities are supported by CIHR, Crohn's and Colitis Canada and their partners to address specific gaps or opportunities related to IBD research. The purpose of focusing on a specific disease, theme or discipline is to address a research gap or develop Canadian research strength. A number of different priority-driven funding mechanisms have been used over the last decade, including research networks and team grants, examples of which are shared later on. Where relevant, leadership of Nominated Principal Investigators and Principal Investigators is acknowledged as indicated in the CIHR Funding Decisions Database. An example of priority-driven research is profiled in Box 2: Project Profile: IBD Genomic Medicine (iGenoMed) Consortium. 
Examples of Priority-Driven Research Networks
Box 2. Project Profile: IBD Genomic Medicine (iGenoMed) Consortium
Funded jointly by CIHR, Genome Canada, Crohn's and Colitis Canada and Genome Quebec ($9.97 million), the objectives of the iGenoMed Consortium were to identify biomarkers of response to therapy and to develop predictive tests to help guide patients and their physicians in their treatment decisions. As part of the iGenoMed research project, Professors John D. Rioux and Alain Bitton, along with their colleagues across Canada and international collaborators, have produced high-impact findings. These include a high-resolution map that was used to investigate which genetic variants have a causal role in IBD 15 and an integrative approach to the development of multi-omic biomarkers of response to therapy 16 . In order to improve the chances of success of this new generation of predictive tests, the iGenoMed Consortium identified potential socioeconomic barriers to acceptance and strategies to address these challenges [17] [18] [19] [20] . These findings will help researchers identify both which genes are involved in playing a role in IBD and which medications might be successful in which patients.
Box 1. Training the Next Generation of IBD Researchers
The CIHR/CCC/CAG Partners Program is an ongoing grants and awards program funded by CIHR and Crohn's and Colitis Canada, and administered by the Canadian Association of Gastroenterology. Originally launched in 1992, this program has funded research fellowships, new investigator awards, career transition awards and operating grants to support gastroenterology research, including a subset in the area of IBD. A 2012 review of this program demonstrated the impact of long-term and collaborative investments in training and capacity building, with recipients of funding producing research publications that had greater scientific impact than publications by peers both in Canada and around the world. 14 The CIHR/CCC/CAG Partners Program demonstrates the effectiveness of organizations collaborating across sectors to support world-class research that will ultimately improve the lives of patients with IBD.
Other examples of collaborative approaches to training the next generation of IBD researchers include partnerships between members of National Alliance of Provincial Health Research Organizations (NAPHRO) and charities such as Crohn's and Colitis Canada, which have resulted in the funding of provincial fellowships, scholarships and other capacity building opportunities. 
OUTPUT AND QUALITY OF IBD RESEARCH IN CANADA
Overview
The collaborative efforts of CIHR, Crohn's and Colitis Canada and other Canadian research funders have supported the development of a strong cadre of Canadian health researchers who have worldwide impact. Inflammatory bowel disease researchers in Canada are among the most internationally collaborative in the world, 21 and Canadian researchers are among those identified as authors of the top 100 cited research manuscripts in IBD worldwide. 22 An example of impactful Canadian IBD Research is detailed in Box 3: International Recognition of Canadian Research Strength in IBD.
Recognition of Canadian Research Strength in IBD
A bibliometric data analysis (see Appendix B for methodology) conducted in 2018 demonstrates the quality of IBD research in Canada. This analysis showed that Canada ranks sixth worldwide in terms of number of IBD scientific papers published (which is equal to Canada's ranking when taking into account all scientific papers published). When productivity and impact in IBD research are combined, Canada is among the top three in the world. Table 4 summarizes the top five countries with the highest bibliometric indices for IBD research between 2012 and 2016. Canada consistently ranked within the top three for each of the three bibliometric measures outlined:
Average Relative Impact Factor (ARIF)
This indicator is a measure of the expected impact of the research portfolio. To account for different citation patterns across fields and subfields, a Relative Impact Factor (RIF) is calculated by dividing the impact factor of the journal that the paper is published in by the mean impact factor of all papers in a particular subfield. The ARIF of a country is then calculated by computing the mean of the RIF of all published papers in a particular discipline for the country. An ARIF value greater than one indicates that the country publishes in journals cited more often than the world average.
Canada's ARIF (1.53) places Canada third internationally in IBD research after the Netherlands and the United Kingdom, with no statistical significance between the results of the top five countries. In terms of all scientific publications, Canada's ARIF is 1.22, which is lower than the ARIF achieved by Canadian IBD-focused researchers.
Average of Relative Citations (ARC)
This indicator measures the observed impact of the research portfolio. It is based on the number of citations received by a published paper over a three-year period following the publication year. The number of citations received by each paper is normalized by the average number of citations received by all papers of the same subfield.
Canada's ARC value in all scientific research for the period measured was 1.42, with IBD research being 2.19. This is well above the IBD world average (1.27) and second only to the Netherlands (2.37), with the difference in score not being statistically significant. This finding means that, on average, papers dealing with IBD topics are cited 1.27 times more often than the average papers of their respective disciplinary field. For example, an IBD paper published in a journal of gastroenterology would be cited more frequently than other papers in gastroenterology. In terms of Canadian IBD papers, these are cited 2.19 times more frequently than other papers in their respective disciplines and 1.72 times more often than the world average of IBD papers. It is also important to note that Canada's ARC is significantly higher than its ARIF, indicating that the IBD research portfolio outperformed expectations over this period.
Box 3. International Recognition of Canadian Research Strength in IBD
The incidence of IBD is now increasing not only in North America and Europe but also in parts of Asia, such as India and China. The increasing incidence of IBD around the world is thought to be linked not only to genetics but also to lifestyle and environmental changes. Canadian researchers are leading the way in identifying how changes in environment such as sanitation, air quality and diet may contribute to the development of IBD. Two Canadian research networks, The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN) and Generational Differences in Environmental Exposure Caused by Migration: Impact on Incidence of Inflammatory Disease (GEMINI) were profiled as worldwide leaders in a Nature Outlook article. 23 These research networks are among the Canadian resources that are helping us understand how environmental exposures can impact the composition of bacteria in the gut (the microbiome) and how we can treat these changes to reduce inflammation.
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Top 10% impact: based on the Relative Citations (RC) measure
From 2012 to 2016, 25% of Canada's published IBD papers were within the top 10% of all IBD published papers, placing Canada second in the world (behind the Netherlands) on this measure.
Although there is a time lag between research funding and publication of data, we assumed relative productivity within plus or minus a three-year time period within a country would not vary significantly. Using this assumption, we created an average dollar investment per published paper by determining the number of published papers in the Dimensions platform that were found in the top 10 bibliometric analysis and then dividing by the research investment. With these limitations, we compared Canada, the United Kingdom and the United States: Canadian funders invested $132,578 for every paper published in the top 10% impact listing. In comparison, the United Kingdom and United States invested $205,053 and $576,316, respectively. Comparative funding data are not available for the Netherlands and France in the Dimensions platform, precluding our ability to include these countries in this comparative analysis.
CONCLUSIONS
Investment in IBD research in Canada has resulted in the development of a strong collaborative group of researchers producing impactful, world-class research. Relatively high levels of investment in all forms of research-including cure, treatment, prevention, health services and policy and quality of life-are likely a response to the prevalence and impact on quality of life of these diseases in Canada. Historically, Canada has been the fourth largest IBD research funder in the world, investing over $119 million from 2013 to 2017. With this investment, the research community has delivered an extraordinary performance. On all measures of academic productivity and influence, Canada ranks in the top two or three internationally.
Against a backdrop of generally constrained resources, the challenge ahead is twofold: to continue to fund innovative, relevant IBD research and grow the next generation of IBD researchers while at the same time moving research findings ever more quickly into changes in health policy and practice in order to benefit affected patients and their families and, ultimately, identify the cause(s) and find the cure(s). These databases do not include all documents likely to have been published by Canadian or foreign researchers, since some works are disseminated through other scientific media not indexed by the WoS (for instance, highly specialized journals, national journals, grey literature and conference proceedings not published in journals). However, the WoS databases include the researchers' scientific output most visible to Canadian and worldwide scientific communities and, therefore, is most likely to be cited.
Given that the WoS subject classification is applied to journals and not individual papers, in order to more specifically identify papers focused on Crohn's disease and colitis, OST used the US National Library of Medicine's Medical Subject Headings (MeSH), which relies on a controlled vocabulary to assign a medical topic to each paper indexed in PubMed. Table 6 presents the MeSH queries selected for this study and the number of papers retrieved in PubMed. Taken together, these three queries retrieved 22,647 papers in PubMed over the 2009 to 2016 period. Due to the structure of the MeSH classification, these queries also cover the following concepts and MeSH terms:
Query #1 includes papers dealing with idiopathic proctocolitis and ulcerative colitis. Query # 2 retrieves papers dealing with Crohn's disease, Crohn's enteritis, granulomatous colitis, granulomatous enteritis, ileocolitis, regional enteritis and terminal ileitis.
It should also be noted that a given paper can bear more than one of these terms, which is why the sum of papers retrieved by each selected query is greater than the total number of distinct papers retrieved by the whole retrieval strategy. Using authors' names, article titles, publication year, journal journal volume, journal number and page numbers, these PubMed papers were matched to corresponding items in the WoS to populate the bibliometric dataset from which the measurement areas identified were calculated.
It should be noted that PubMed records do not necessarily have a corresponding item in the WoS. Among the 22,647 papers retrieved from PubMed, 20,245 were published in a journal indexed in the WoS. Among these, 18,967 were matched to a record bearing at least one institutional address and corresponding to the document types used in the bibliometric analysis: articles, research notes and review articles because they are all considered as vehicles of new knowledge).
Details about the methodology have been published over the years. [24] [25] [26] What follows is a synopsis of the key elements.
Indicators
For the 10 most productive countries in IBD research, the following indicators were produced at the level of each country and each priority area.
Number of publications
The number of scientific papers with authors from a country, as identified in the authors' addresses, were counted. Although OST's database includes several types of documents, only articles, research notes and review papers are included as described previously because these are the primary means of disseminating new knowledge. This indicator is also presented as a percentage of world papers in which at least one institutional address is from the country. These numbers of publications are also compiled for Canadian institutions and sectors (university, hospitals, industries, federal government, provincial government and others).
Specialization index (SI)
This is an indicator of the relative intensity of publication of a country in the priority areas identified relative to the intensity of the world in the same areas. An SI value above one means that a country is specialized in the priority area compared with the world average, whereas an index value below one means the opposite.
Average relative impact factor (ARIF)
This indicator provides a measure of the scientific impact of the journals in which a group of researchers publish. Each journal has an impact factor (IF), which is calculated annually based on the average number of citations received by the papers it published during the two previous years. The value of a journal's IF is assigned to each paper it publishes. In order to account for different citation patterns across fields and subfields (e.g., there are more citations in biomedical research than mathematics), each paper's IF is then divided by the average IF of the papers in its particular subfield in order to obtain a Relative Impact Factor (RIF). The ARIF of a given institution (or group of researchers) is computed using the average RIF of all papers belonging to it. When the ARIF is greater than one, it means that this institution (or group of researchers) publishes in journals cited more often than the world average; when it is below one, the institution (or group of researchers) publishes in journals that are not cited as often as the world average. This indicator is set to nonsignificant when the number of publications involved is below 30.
Average of Relative Citations (ARC)
This indicator is based on the number of citations received by a published paper over a three-year period following the publication year. Thus, for papers published in 2000, citations received between 2000 and 2003 are counted. Author self-citations are included. The number of citations received by each paper is normalized by the average number of citations received by all papers of the same subfield, taking into account the fact that citation practices are different for each specialty. When the ARC is greater than one, it means that a paper or a group of papers scores better than the world average of its specialty; when it is below one, those publications are not cited as often as the world average. It should also be noted that this indicator is set to nonsignificant when the number of publications involved is below 30.
Top 10% impact (RC)
This indicator is based on the value of the relative citation (RC). Each paper has a RC that is the number of citations it receives normalized (divided) by the average number of citations received by all papers published the same year in the same specialty. The top 10% impact (RC) are the papers with the RC value in the top 10% of all papers published in the same year in the same specialty. Journal of the Canadian Association of Gastroenterology, 2019, Vol. 2, No. S1 S91
